REPORT ID 3686

United States C Difficile Infection Drug Market Report 2017

Publish Date
14-Dec-17
Pages
112
Format
Electronic (PDF)

In this report, the United States C Difficile Infection Drug market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:
    The West
    Southwest
    The Middle Atlantic
    New England
    The South
    The Midwest
with sales (volume), revenue (value), market share and growth rate of C Difficile Infection Drug in these regions, from 2012 to 2022 (forecast).

United States C Difficile Infection Drug market competition by top manufacturers/players, with C Difficile Infection Drug sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    Merck
    Astellas
    Eli Lilly
    ANI Pharmaceutical
    Flynn Pharma
    Aspen Pharmacare
    Akorn
    Merus labs
    Pfizer
    AstraZeneca
    Strides
    Sanofi
    Fresenius
    Xellia
    Zhejiang Medicine
    Lupin

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
    Metronidazole
    Vancomycin
    Fidaxomycin
    Others
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of C Difficile Infection Drug for each application, including
    Pre-treatment
    Mid-term treatment
    Others

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

United States C Difficile Infection Drug Market Report 2017
1 C Difficile Infection Drug Overview
    1.1 Product Overview and Scope of C Difficile Infection Drug
    1.2 Classification of C Difficile Infection Drug by Product Category
        1.2.1 United States C Difficile Infection Drug Market Size (Sales Volume) Comparison by Type (2012-2022)
        1.2.2 United States C Difficile Infection Drug Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
        1.2.3 Metronidazole
        1.2.4 Vancomycin
        1.2.5 Fidaxomycin
        1.2.6 Others
    1.3 United States C Difficile Infection Drug Market by Application/End Users
        1.3.1 United States C Difficile Infection Drug Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
        1.3.2 Pre-treatment
        1.3.3 Mid-term treatment
        1.3.4 Others
    1.4 United States C Difficile Infection Drug Market by Region
        1.4.1 United States C Difficile Infection Drug Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 The West C Difficile Infection Drug Status and Prospect (2012-2022)
        1.4.3 Southwest C Difficile Infection Drug Status and Prospect (2012-2022)
        1.4.4 The Middle Atlantic C Difficile Infection Drug Status and Prospect (2012-2022)
        1.4.5 New England C Difficile Infection Drug Status and Prospect (2012-2022)
        1.4.6 The South C Difficile Infection Drug Status and Prospect (2012-2022)
        1.4.7 The Midwest C Difficile Infection Drug Status and Prospect (2012-2022)
    1.5 United States Market Size (Value and Volume) of C Difficile Infection Drug (2012-2022)
        1.5.1 United States C Difficile Infection Drug Sales and Growth Rate (2012-2022)
        1.5.2 United States C Difficile Infection Drug Revenue and Growth Rate (2012-2022)

2 United States C Difficile Infection Drug Market Competition by Players/Suppliers
    2.1 United States C Difficile Infection Drug Sales and Market Share of Key Players/Suppliers (2012-2017)
    2.2 United States C Difficile Infection Drug Revenue and Share by Players/Suppliers (2012-2017)
    2.3 United States C Difficile Infection Drug Average Price by Players/Suppliers (2012-2017)
    2.4 United States C Difficile Infection Drug Market Competitive Situation and Trends
        2.4.1 United States C Difficile Infection Drug Market Concentration Rate
        2.4.2 United States C Difficile Infection Drug Market Share of Top 3 and Top 5 Players/Suppliers
        2.4.3 Mergers & Acquisitions, Expansion in United States Market
    2.5 United States Players/Suppliers C Difficile Infection Drug Manufacturing Base Distribution, Sales Area, Product Type

3 United States C Difficile Infection Drug Sales (Volume) and Revenue (Value) by Region (2012-2017)
    3.1 United States C Difficile Infection Drug Sales and Market Share by Region (2012-2017)
    3.2 United States C Difficile Infection Drug Revenue and Market Share by Region (2012-2017)
    3.3 United States C Difficile Infection Drug Price by Region (2012-2017)

4 United States C Difficile Infection Drug Sales (Volume) and Revenue (Value) by Type (Product Category) (2012-2017)
    4.1 United States C Difficile Infection Drug Sales and Market Share by Type (Product Category) (2012-2017)
    4.2 United States C Difficile Infection Drug Revenue and Market Share by Type (2012-2017)
    4.3 United States C Difficile Infection Drug Price by Type (2012-2017)
    4.4 United States C Difficile Infection Drug Sales Growth Rate by Type (2012-2017)

5 United States C Difficile Infection Drug Sales (Volume) by Application (2012-2017)
    5.1 United States C Difficile Infection Drug Sales and Market Share by Application (2012-2017)
    5.2 United States C Difficile Infection Drug Sales Growth Rate by Application (2012-2017)
    5.3 Market Drivers and Opportunities

6  United States C Difficile Infection Drug Players/Suppliers Profiles and Sales Data
    6.1 Merck
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 C Difficile Infection Drug Product Category, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Merck C Difficile Infection Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Astellas
        6.2.2 C Difficile Infection Drug Product Category, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Astellas C Difficile Infection Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Eli Lilly
        6.3.2 C Difficile Infection Drug Product Category, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Eli Lilly C Difficile Infection Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 ANI Pharmaceutical
        6.4.2 C Difficile Infection Drug Product Category, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 ANI Pharmaceutical C Difficile Infection Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Flynn Pharma
        6.5.2 C Difficile Infection Drug Product Category, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Flynn Pharma C Difficile Infection Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Aspen Pharmacare
        6.6.2 C Difficile Infection Drug Product Category, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Aspen Pharmacare C Difficile Infection Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Akorn
        6.7.2 C Difficile Infection Drug Product Category, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Akorn C Difficile Infection Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 Merus labs
        6.8.2 C Difficile Infection Drug Product Category, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Merus labs C Difficile Infection Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 Pfizer
        6.9.2 C Difficile Infection Drug Product Category, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 Pfizer C Difficile Infection Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview
    6.10 AstraZeneca
        6.10.2 C Difficile Infection Drug Product Category, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 AstraZeneca C Difficile Infection Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.10.4 Main Business/Business Overview
    6.11 Strides
    6.12 Sanofi
    6.13 Fresenius
    6.14 Xellia
    6.15 Zhejiang Medicine
    6.16 Lupin

7 C Difficile Infection Drug Manufacturing Cost Analysis
    7.1 C Difficile Infection Drug Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of C Difficile Infection Drug

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 C Difficile Infection Drug Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of C Difficile Infection Drug Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 United States C Difficile Infection Drug Market Size (Value and Volume) Forecast (2017-2022)
    11.1 United States C Difficile Infection Drug Sales Volume, Revenue Forecast (2017-2022)
    11.2 United States C Difficile Infection Drug Sales Volume Forecast by Type (2017-2022)
    11.3 United States C Difficile Infection Drug Sales Volume Forecast by Application (2017-2022)
    11.4 United States C Difficile Infection Drug Sales Volume Forecast by Region (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer